Surgery Effective Against Immune Disorder That Weakens Muscles
Myasthenia gravis affects 60,000 Americans, but removal of thymus gland appears to help, research shows Source: HealthDay Related MedlinePlus Page: Myasthenia Gravis
Myasthenia Gravis (MG) is a chronic autoimmune disease (AID) with a prevalence of 1-2 per 10.000 . The clinical hallmark is fluctuating weakness of striated muscles with antibodies directly affecting the neuromuscular junction. In approximately 85% of patients, the initial presenting symptoms are asymmetric ptosis and/or diplopia. Approximately 80% of initially ocular MG patients will develop generalized MG within two years of disease onset .
Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. Broad-based immunotherapies, such as corticosteroids, azathioprine, mycophenolate, tacrolimus, and cyclosporine, have been effective in controlling symptoms of myasthenia. While being effective in a majority of MG patients many of these immunosuppressive agents are associated with long-term side effects, often intolerable for patients, and take several months to be effective. With advances in translational research and drug development capabilities, more directed therapeutic agents that can alter ...
Psychopathology and personality traits may influence the course of autoimmune disorders. With this prospective longitudinal cohort study, we aimed to assess personality, stress and depression in myasthenia pat...
olker Straub We identified the known c.1_9del mutation in the PLEC gene in four unrelated females from consanguineous families of Turkish origin. All individuals presented with slowly progressive limb-girdle weakness without any dermatological findings, and dystrophic changes observed in their muscle biopsies. Additionally, the neurological examination revealed ptosis, facial weakness, fatigability, and muscle cramps in all four cases. In two patients, repetitive nerve stimulation showed a borderline decrement and a high jitter was detected in all patients by single-fiber electromyography. Clinical improvement was obse...
ConclusionPatients with MG are vulnerable to social, professional, and mental disadvantages. Therapeutic success in MG goes beyond symptom relief and inevitably depends on a personalized approach to the patient.
Since 2004, the Food and Drug Administration (FDA) has released eight safety communications regarding serious adverse effects associated with fluoroquinolones, including peripheral neuropathy, tendonitis/tendon rupture, worsening of myasthenia gravis, central nervous system effects (confusion, hallucinations), hypoglycemia, QTc prolongation, and aortic tear/rupture. An FDA Boxed Warning was issued to reserve use of fluoroquinolones for patients with no alternative treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections.
Conclusion: The conclusion of this study will achieve convincing evidence to evaluate the effectiveness and safety of thymectomy plus prednisone for the treatment of non-thymomatous MG. PROSPERO registration number: CRD 42020167735.
No abstract available
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study proves that the use of plasmapheresis conducted by filtration in the treatment of autoimmune neurological diseases is safe and well tolerated. PMID: 32557528 [PubMed - as supplied by publisher]